1 Several compounds, mainly opioid agonists such as methadone, are currently used for long term medication of heroin addicts. Nevertheless, these maintenance treatments have the disadvantage to induce a dependence to another opiate. As interactions between opioid and cannabinoid systems have been demonstrated, the ability of the CB 1 antagonist, SR141716A to reduce morphine-induced addiction was investigated. 2 The eects of SR141716A on the rewarding responses of morphine were evaluated in the place conditioning paradigm. No signi®cant conditioned preference or aversion were observed after repeated treatment with the CB 1 antagonist alone. However, SR141716A was able to antagonize the acquisition of morphine-induced conditioned place preference. 3 SR141716A was co-administered with morphine for 5 days, and the withdrawal syndrome was precipitated by naloxone administration. A reduction in the incidence of two main signs of abstinence: wet dog shakes and jumping was observed while the other were not signi®cantly modi®ed. In contrast, an acute injection of the CB 1 antagonist just before naloxone administration was unable to modify the incidence of the behavioural manifestations of the withdrawal, suggesting that only chronic blockade of CB 1 receptors is able to reduce morphine-induced physical dependence. 4 Several biochemical mechanisms could explain the reduction of opioid dependence by CB 1 antagonists. Whatever the hypotheses, this study supports the reported interaction between the endogenous cannabinoid and opioid systems, and suggests that SR 141716A warrants further investigations for a possible use in opioid addiction.
Introduction
Since drug addiction is often considered as a chronic, relapsing disorder, several therapeutical assays to reduce craving are under investigation. In the case of opiate addicts, long-term treatment with opioid agonists such as methadone or buprenorphine, are currently used (review in Kreek, 1997; Fischer et al., 1999; Ward et al., 1999) . Nevertheless, there are several reasons why it should be of great interest to use non-opioid substances for maintenance treatments or detoxi®cation of heroin abusers. Firstly, like heroin, methadone and buprenorphine used in maintenance program could generate a psychological dependence and can be diverted to illegal sales. Secondly, as an opioid agonist, methadone is able to trigger a withdrawal syndrome and even though it is less severe than that observed with heroin, it is longer lasting. Furthermore, physical dependence has also been reported to occur after chronic buprenorphine treatment (Kuhlman et al., 1998; Dyer et al., 1999) .
Opioids and cannabinoids share several pharmacological properties (Dewey, 1986) , both leading for example to analgesia (Lichtman & Martin, 1991) , hypothermia (Anderson et al., 1975) and reduced locomotor activity at high doses (Anderson et al., 1975) . Moreover, several lines of evidence support the occurrence of interactions between both systems (Welch et al., 1995; Tanda et al., 1997; Meng et al., 1998; whereas reinforcing properties of the alkaloid and severity of the withdrawal syndrome were found to be reduced, suggesting that long-term CB 1 antagonist administration could be considered for preventing the development of dependence to opiates. However, frequent inconsistencies between observed and expected results are found in knockout mice, probably due to compensatory developmental mechanisms occurring during embryogenesis and early postnatal life (Zimmer et al., 1998; de Felipe et al., 1998) . It was therefore of interest to investigate the eect resulting from the blockade of the CB 1 receptors by an antagonist using wild type mice. The synthesis of the highly potent and selective CB 1 antagonist, SR 141716A (N-(piperidin-1-yl)-5-(4-chlorophenyl) -1-(2,4-dichlorophenyl) -4-methyl-1H-pyrazole-3-carboxyamide (Rinaldi-Carmona et al., 1994) aords the possibility to evaluate this hypothesis and to determine whether chronic blockade of CB 1 receptors could be used to facilitate drug abstinence.
We have therefore studied the behavioural changes classically observed following chronic morphine treatment i.e. withdrawal syndrome and rewarding properties (review in Koob & Le Moal, 1997) in mice repeatedly treated with the combination morphine+SR 141716A. Moreover, as numerous studies have reported a link between both k and cannabinoid systems (Smith et al., 1994; Welch, 1997) we have evaluated the eects of chronic SR 141716A treatment on the levels of k endogenous opioid peptide, dynorphin, as well as k opioid receptors. Indeed, stimulation of k opioid receptors in the nucleus accumbens was shown to negatively modulate the rewarding properties of morphine. This occurs by a decrease in synaptic levels of dopamine induced by opioid activation of the mesolimbic dopaminergic pathway (Di Chiara & Imperato, 1988; Spanagel et al., 1992; Kuzmin et al., 1997) .
Methods

Animals
Male CD-1 mice (Charles River, France) weighing 20 ± 22 g at the start of the experiments, were housed in groups of 20 at least 2 days before the chronic treatments, and maintained at a controlled temperature of 21+18C. -THC (THC) (Sigma, France) was dissolved into a ®nal concentration of 10% ethanol, 10% cremophor EL (Sigma) and 80% distilled water and injected via the intraperitoneal (i.p.) route. The CB 1 receptor antagonist SR 141716A (generously provided by Sano® Recherche, France) was dissolved in a solution of 5% ethanol, 5% cremophor EL and 90% distilled water and injected i.p. Morphine (Francopia, France) and naloxone (Sigma, France) were dissolved in saline (0.9% sodium chloride in water) and injected i.p. and via the subcutaneous (s.c.) route, respectively. Volumes of injection were 0.1 ml per 10 g of body weight. 
Chemicals
Place conditioning paradigm
To evaluate the eects of SR 141716A on the rewarding properties of morphine, an unbiased place conditioning methodology was used. Tests were performed as previously reported (Valverde et al., 1996a) except for the conditioning time (20 min) and the size of the compartments which were adapted for studies with mice (15615615 cm). Brie¯y, the protocol consisted of three phases. (1) The preconditioning phase, where drug naive mice had free access to both compartments of the conditioning apparatus for 20 min with the time spent in each compartment recorded. (2) The conditioning phase, during which mice were treated for 6 consecutive days with alternate injections of drug or vehicle, and immediately placed individually in one of the conditioning environments for 20 min. Mice received the drug on days 1, 3 and 5, and vehicle on days 2, 4 and 6. Control animals received vehicle every day. (3) The postconditioning or testing phase, was conducted exactly as the preconditioning phase (free acces to each compartment for 20 min) 24 h after the last conditioning session. Separate groups of mice (n=8 ± 10 per group) received morphine (3 mg kg
71
, i.p.), SR 141716A (1, 5 or 10 mg kg 71 , i.p), morphine+SR 141716A (used at the dierent doses previously mentioned) or vehicle injection. Data were compared using Newman-Keuls's test, after main eect of ANOVA on score (calculated as the dierence between postconditioning and preconditioning time spent in the compartment associated with the drug).
Measurement of withdrawal syndrome
Experiment 1 Four groups of mice (n=7 ± 9 per group) were injected i.p. twice daily for 5 days with morphine, SR 141716A (10 mg kg , i.p.) to precipitate the withdrawal syndrome, the signs of which were observed for 40 min (writhing, sning, wet-dog shakes, paw to face, ataxia, body tremor, ptosis, and piloerection).
Experiment 3 Four groups of mice (n=10 per group) were injected i.p. twice daily for 5 days with morphine (two groups) or saline (two groups). The morphine dose was progressively increased as described in experiment 1. On day 6, the mice only received one injection in the morning of morphine (100 mg kg 
Statistical analysis
Somatic signs of withdrawal were compared by using a oneway ANOVA (between subjects) using post hoc NewmanKeuls's test.
Binding on brain homogenates
Mice were chronically treated in the same conditions used to evaluate the withdrawal syndrome after administration of naloxone. On day 6, mice were killed by decapitation. Whole brains minus cerebellum were dissected, homogenized in TrisHCl buer 50 mM, EDTA 1 mM (pH 7.4), and centrifuged at 35,000 r.p.m. for 30 min at 48C. The pellet was homogenized in 5 ml ice-cold 50 mM Tris-HCl, 1 mM EDTA. The binding was performed using 100 mg of total brain membrane proteins incubated in 50 mM Tris-HCl pH 7.4, 1 mM EDTA at 258C for 1 h with (
at concentrations of 0.01 ± 1.28 nM. Naloxone was used at a 2 mM concentration to determine non-speci®c binding. Experiments were performed in triplicate using at least three distinct membrane preparations. Binding data were analysed using the EBDA-LIGAND program (Biosoft).
Dynorphin A radioimmunoassay (RIA)
The RIA was carried out using a radioimmunoassay kit for dynorphin A from the Phoenix Pharmaceuticals Inc. (Belmont, CA, U.S.A.), following the supplier's instructions.
Results
Place preference paradigm
The eects of the dierent doses of SR 141716A (1, 5 and 10 mg kg 71 ) on the rewarding properties of morphine were investigated. As shown in Figure 1 , morphine administration (3 mg kg 71 , i.p.) induced a clear conditioned place preference, indicated by a signi®cant increase in the time spent in the drug-associated compartment during the testing phase, whereas no place preference was observed in the vehicle group. At the lowest dose of SR 141716A used (1 mg kg 71 ) no modi®cation of the rewarding properties of morphine were observed (Figure 1a ), whereas at higher doses (5 mg kg 71 and 10 mg kg 71 ), the reinforcing properties of the alkaloid were totally abolished (Figure 1b,c) .
Physical dependence
Experiment 1 In this experiment, mice were chronically treated with morphine (5 days) alone or in association with the CB 1 antagonist SR 141716A. Then, the withdrawal syndrome was precipitated by administration of the opioid antagonist naloxone. A decrease in the incidence of two main signs of physical dependence to opiates, i.e. wet dog shakes and jumping was observed in mice chronically treated with morphine+SR 1451716A as compared to morphine-treated mice, whereas other signs (paw tremor, ptosis, sning, body tremor) of naloxone precipitated withdrawal were not dierent between both groups (Figure 2) . Experiment 2 Most of the withdrawal signs observed after administration of the CB 1 antagonist (10 mg kg 71 ) in mice chronically treated with THC (wet dog shakes, paw to face, piloerection, ptosis, writhing and sning) were totally abolished in animals chronically treated with THC+SR 141716A. The only exceptions were ataxia and body tremor (Figure 3) . Experiment 3 Mice chronically treated with morphine for 5 days received on day 6 a last injection of morphine alone or in association with SR 141716A, and 2 h later the withdrawal 
Biochemical experiments
As reported in Table 1 , similar K D and B max values were obtained for k opioid receptors on whole brain membranes using a speci®c radioligand ( 3 H)CI-977 in the four dierent groups of mice chronically treated with vehicle, morphine, SR 141716A (10 mg kg 71 ) or morphine+SR 141716A combination. Moreover, no modi®cation in the dynorphin levels were observed in the dierent groups of animals, determined using a radioimmunoassay (Table 2 ) performed on whole brain.
Discussion
The aim of this study was to investigate the eects of repetitive treatment with the cannabinoid CB 1 antagonist SR 141716A on physical and psychological dependencies induced by chronic morphine administration. Regarding physical dependence, the opioid antagonist naloxone produced withdrawal signs which were not found to be very dierent in mice chronically treated with morphine alone or with the combination morphine+SR 141716A except for the two main withdrawal signs (wet dog shakes and jumping) which were signi®cantly reduced (Figure 2) . The observed SR 141716A-evoked withdrawal signs in mice chronically treated with THC, were abolished in animals repeatedly treated with the combination THC+SR 141716A, suggesting that the ) used during chronic morphine treatment was sucient to block the CB 1 receptors. The present results indicate that only long term CB 1 antagonist administration mimicking the situation encountered in CB 1 receptor deleted mice, reduces development of morphine physical dependence. According to this hypothesis, an acute administration of SR 141716A was unable to modify the naloxone-precipitated withdrawal signs in chronically morphine-treated mice. There is some disparity between the eects observed in the present study and in CB 1 receptor knock-out mice, as in the latter (Ledent et al., 1999) , seven of the nine signs of naloxone-precipitated morphine withdrawal evaluated were found signi®cantly reduced. This observation, taken with the present results, indicates that the duration of the CB 1 receptor blockade could modulate the intensity of the morphine withdrawal syndrome expression. This hypothesis suggests that results obtained in knock-out mice should be carefully considered before any extrapolation and require additional experiments with wild type animals and selective antagonists blocking reversibly the receptor.
On the other hand, the results show that SR 141716A (5 mg kg
71
) antagonized the acquisition of morphine-induced conditioned place preference. This result is in agreement with the experiments of Ledent et al. (1999) showing that the number of nose pokes leading to morphine administration was much lower in CB 1 receptor knockout mice as compared to wild type animals. In the present study a possible trend towards conditioned place aversion was observed though it was not signi®cant after three drug paired conditioning periods with the highest doses, 5 and 10 mg kg
. This could be due to side-eects, such as paw tremors, head shakes or ataxia, observed after administration of high doses of the CB 1 antagonist (Cook et al., 1998) . It is interesting to notice that invalidation of the CB 1 receptor was also reported to generate mice with problems of ataxia and hypolocomotion (Zimmer et al., 1999) . Another hypothesis to explain the results obtained is the existence of an endogenous cannabinoid tone, as several authors observed that CB 1 agonists are able to induce a place preference (Lepore et al., 1995; Valjent & Maldonado, 2000) . However, it is important to note that the rewarding eects of cannabinoids in the dierent animals models currently used are controversial and may strongly depend in part of the species and treatments used (Harris et al., 1974; Mansbach et al., 1994) . Thus, cannabinoid agonists failed to induce self-administration behaviour in monkeys or rats (Leite & Carlini, 1974) , but are self-administered in mice (Martellota et al., 1998) . Several hypotheses could be proposed to explain the present results. The well-known dysphoric eects of THC at high concentrations may likely reduce the rewarding eects of opioids (Hutcheson et al., 1998; Valjent & Maldonado, 2000) . Furthermore, as it is well established that k agonists have aversive properties, it could be speculated that the lack of morphine reinforcing eects in mice chronically treated with the combination morphine+SR 141716A results from an alteration of the k opioid system, which may counteract the rewarding eects of the alkaloid (Spanagel et al., 1992) . However, this hypothesis appears unlikely as no modi®cation in the level of dynorphin (the endogenous ligand of the k opioid receptor) and in the binding parameters of k opioid receptors were observed in morphine+SR 141716A-treated mice as compared to morphine-, SR 141716A-or vehicle-treated mice. Other hypotheses could be suggested to account for the reduction of morphine-induced dependence in mice concomitantly treated with the alkaloid and the CB 1 antagonist. One of them involves a modulation in the release of hypothalamic corticotropin releasing factor (CRF), well known to be involved in determining propensity to develop drug addiction (Shaham et al., 1998; Rouge-Pont et al., 1998) . Accordingly CRF-containing neurons and CB 1 receptors were found colocalized in hypothalamic and limbic areas such as amygdala complex, the medial prefrontal cortex or the hippocampus (Swanson et al., 1983; Herkenham et al., 1991) . As in a previous study it has been shown that the endogenous ligand of CB 1 receptors, anandamide parallels THC in activation of hypothalamo-pituitary-adrenal (HPA) axis via mediation of a central mechanism which involves the secretion of CRF (Weidenfeld et al., 1994) , it could be speculated that blockade of CB 1 receptor with SR 141716A reduces the endogenous activity of the HPA axis, leading to a reduction of morphineinduced rewarding eects. On the other hand, the CB 1 receptor may exist in dierent states, an inactive state precoupled (Vasquez & Lewis, 1999) or not (Bouaboula et al., 1997) to G i/o in its GDP-bound form and an active R* state coupled to G i/o in its GTP-bound form. SR 141716A may contribute to stabilize the inactive R-GDP state of the receptor due to its inverse agonist properties (Bouaboula et al., 1997) , sequestering a pool of G i/o -proteins, making them unavailable to couple to other receptors, such as mu opioid receptors, almost exclusively involved in morphine addiction (Matthes et al., 1996) . Thus, long term adaptation in intracellular messenger proteins along the cyclic AMP pathway which is a mechanism likely to be involved in opiate addiction (Nestler et al., 1993) may be less marked in presence of the CB 1 antagonist. As there is now evidence for a role of the upregulated cyclic AMP pathway in opiate dependence (Maldonado et al., 1995; Valverde et al., 1996b; Punch et al., 1997) , this hypothesis could explain the reduction in development of physical dependence and acquisition of morphine-induced reinforcement in the conditioning place preference paradigm. This is reinforced by the presence of both opioid and CB 1 receptors in the same brain areas (Navarro et al., 1998) , including the limbic system, wellknown to play a major role in rewarding processes (review in Koob & Le Moal, 1997) .
In conclusion, the present study shows that the CB 1 antagonist SR 141716A co-administered with morphine is able to abolish the rewarding eects of the alkaloid, investigated in the place preference paradigm and to diminish the naloxone-precipitated withdrawal syndrome in mice. These results support an interaction between the endogenous cannabinoid and opioid systems. Whilst the results obtained could be predicted on the basis of the observation that the morphine eects were diminished in CB 1 receptor knock-out mice (Ledent et al., 1999) , it was essential to reproduce the eects by the pharmacological administration of an antagonist in wild-type animals. Indeed, adaptative compensatory mechanisms may produce unexpected results, as gene deletion is operative during embryogenesis (Zimmer et al., 1998; de Felipe et al., 1998) . The reduction in rewarding responses induced by SR 141716A in mice chronically treated with morphine supports the use of the CB 1 antagonist to prevent withdrawal in heroin addicts. This could be an inconvenience for maintenance treatment with methadone (or buprenorphine) since SR 141716A blocks the rewarding eects of the opiate substitutes. However, well chosen doses of the CB 1 antagonist and methadone could gradually reduce the psychological dependence to the latter, reducing its often reported drawback (Steinpreis et al., 1996) . This hypothesis warrants further investigations with other CB 1 antagonists devoid of the inverse agonist properties of SR 141716A (Bouaboula et al., 1997; Landsman et al., 1997) .
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